The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it buy, with a mean price target of $6497.
Japan Tobacco Inc.
2914.T · JPX · USD · Market cap $12.33T
Japan Tobacco Inc., a tobacco company, engages in the manufacture and sale of tobacco products in Japan and internationally.
FAIL · Does not pass the screenScreen close, 2026-09-25 · not a live quote
Last reviewed 10 days ago
Screened 2026-09-25 · the tape above runs as of 11:17 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
What this means: price 6,943.00 against the desk's fair-value range, base estimate 6,596.04, over the last year.
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Japan Tobacco Inc. holds its Distribution at $6,943.00. The statistical read favours the sellers, held for 41 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the sellers, held for 41 days |
| Price at the screen | $6,943.00 |
| Valuation | 20.49 trailing · 23.06 forward price to earnings |
| Values screen | FAIL |
| Beta | 0.15 |
Five Screens, Shown in Full
Does not pass. Business activity: tobacco
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Its core business involves an activity the values screen does not clear. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Japan Tobacco does not clear the screen at the business-activity stage. It operates in tobacco, so the financial ratios are not the deciding factor here.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value range in USD, drawn from the 2026-09-25 screen. The gold marker is the market price at the same screen. The price runs 5.0% above the base estimate.
Third-party analyst targets: 13 covering, consensus Buy. The average target sits +4% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-25 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | 23.1xpriced for continued growth |
| Trailing P/E | 20.5xa premium valuation |
| EPS, trailing | 338.82 |
| EPS, forward | 301.11 |
| Revenue growth | +17.0%steady growth |
| Profit margin | 16.7%healthy profit margins |
| Return on equity | 14.3%a solid return on shareholder capital |
| FCF yield | 2.10% |
| Debt to equity | 0.38minimal debt: a conservative balance sheet |
| Current ratio | 2.04comfortably covers its short-term bills |
| Beta | 0.15barely tracks the market's swings |
| 52-week range | 4,748.00 - 7,218.00 |
| Moat | STRONG |
| Market cap | $12.33T |
The risks · The things to watch: its business and earnings are exposed to Japan and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade2914.T trades on JPX (the company is based in Japan). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it buy, with a mean price target of $6497.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it buy, with a mean price target of $6497.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it buy, with a mean price target of $6497.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it buy, with a mean price target of $6497.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Is Bunzl (BZLFY) Outperforming Other Consumer Staples Stocks This Year? Zacks · 26d ago
- Bear of the Day: Turning Point Brands (TPB) Zacks · 4 Sep 2026
- Altria Group (MO): A Winner in President Trump’s Stock Portfolio? Insider Monkey · 28 Jul 2026
- Is Bunzl (BZLFY) Outperforming Other Consumer Staples Stocks This Year? Zacks · 22 Jul 2026
- Altria vs. Turning Point Brands: Which Tobacco Stock Is a Better Buy in 2026? Motley Fool · 9 Jul 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $6,164.00 | +0.0% | · | $1,000 | +0.0% |
| 2 months | $5,973.00 | +3.2% | · | $1,032 | +3.2% |
| 3 months | $5,660.00 | +8.9% | · | $1,089 | +8.9% |
| 6 months | $5,639.75 | +9.3% | $130.00 | $1,116 | +11.6% |
| 1 year | $4,197.10 | +46.9% | $234.00 | $1,524 | +52.4% |
| 2 years | $4,165.17 | +48.0% | $428.00 | $1,583 | +58.3% |
| 3 years | $2,703.92 | +128.0% | $622.00 | $2,510 | +151.0% |
| 5 years | $1,648.15 | +274.0% | $950.00 | $4,316 | +331.6% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever 2914.T does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.